Hot Investor Mandate: USA & China-Based VC Firm Highly Interested in Pre-Clinical to Phase II Novel Therapeutics, and Medical Devices

6 Feb

Founded in 2016, the firm has offices in USA and China. The firm has two RMB funds and one USD fund: The two RMB funds focus on the local Chinese market; while the USD fund invests in Hong Kong and non-China market. The firm’s USD Fund has invested in 7 companies, half of which are in the novel drugs area, and will continue to invest in Seed to pre-Series A. The typical allocation size will be $0.5MM to $1 MM, and up to $3.5 MM.

The firm is mainly interested in the Therapeutics innovations including orphan drugs, that are in pre-clinical to Phase II stage, especially CAR-T, small molecules and CRISPR. The firm is also open to medical devices companies, which are in development or clinical stage, but holds a strict valuation on diagnostics companies. The firm is not interested in Healthcare IT.

The firm has no specific company & management Team Requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: